Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03176784 · ClinicalTrials.gov registry record · Phase 4
UW Quitting Using Intensive Treatment Study (QUITS)
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,251
- Enrollment target
NCT03176784: Completed Phase 4 study, sponsored by University of Wisconsin, Madison.
NCT03176784 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 1,251 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (142% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03176784, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,251 participants
- Enrollment target
Study Summary
This research will determine whether two highly promising modifications to varenicline treatment (i.e. use of a nicotine patch adjuvant and extended 24-week duration) produce superior smoking outcomes when they are either used together or alone. Despite their promise, the proposed modifications have never been experimentally evaluated relative to standard varenicline pharmacotherapy. Thus, this innovative research will produce novel evidence regarding how best to help smokers quit, and thereby address the leading cause of preventable mortality and morbidity related to cardiovascular and pulmonary diseases.
Primary Outcome
Biochemically-confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.
Interventions
- DRUG Varenicline
- DRUG Nicotine patch
- OTHER Placebo Patch
- OTHER Placebo Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,251 participants |
| Start Date | 2017-11-11 |
| Est. Completion | 2020-07-09 |
| Phase | Phase 4 |
What the finished NCT03176784 record still lists
NCT03176784 is an interventional study that assigns participants to a tested intervention. Its 1,251 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (142% higher).
The record links to 0 conditions, and to 4 interventions - of which Varenicline is the first listed.
NCT03176784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03176784 about?
NCT03176784 is a clinical study titled "UW Quitting Using Intensive Treatment Study (QUITS)". This research will determine whether two highly promising modifications to varenicline treatment (i.e. use of a nicotine patch adjuvant and extended 24-week duration) produce superior smoking outcomes when they are either used together or alone. Despite their promise, the proposed modifications have...
What is the current status of trial NCT03176784?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,251 participants. The study started on 2017-11-11. Estimated completion is 2020-07-09.
What interventions are being tested in trial NCT03176784?
The interventions under investigation include: Varenicline (DRUG), Nicotine patch (DRUG), Placebo Patch (OTHER), Placebo Pill (OTHER).
Who is sponsoring clinical trial NCT03176784?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03176784's enrollment target sits among peer trials
1,251 62nd of 2000 higher than 1,939 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI